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Abstract Coeliac disease (CD) is an immune-mediated sys-
temic condition elicited by gluten and related prolamines in
genetically predisposed individuals and characterised by
gluten-induced symptoms and signs, specific antibodies, a
specific human leukocyte antigen (HLA) type and enteropa-
thy. The risk of coeliac disease is increased in first-degree
relatives, certain syndromes including Down syndrome and
autoimmune disorders. It is thought to occur in 1 in 100–200
individuals, but still only one in four cases is diagnosed.
Small-bowel biopsy is no longer deemed necessary in a sub-
group of patients, i.e. when all of the following are present:
typical symptoms or signs, high titres of and transglutaminase
antibodies, endomysial antibodies, and HLA-type DQ2 or
DQ8. In all other cases, small-bowel biopsy remains manda-
tory for a correct diagnosis. Therapy consists of a strictly
gluten-free diet. This should result in complete disappearance
of symptoms and of serological markers. Adequate follow-up
is considered essential. Conclusion: Although small-bowel bi-
opsy may be omitted in a minority of patients, small-bowel
biopsy is essential for a correct diagnosis of CD in all other
cases. Diagnostic work-up should be completed before treat-
ment with gluten-free diet instituted.
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Introduction
Coeliac disease (CD; gluten intolerance) is an immune-
mediated systemic condition elicited by gluten and related
prolamines in genetically predisposed individuals. It is charac-
terised by a variable combination of gluten-induced symptoms
and signs, specific antibodies, a specific human leukocyte
antigen (HLA) type (DQ2 or DQ8) and enteropathy [38]. This
new definition, which was very recently coined by a working
group of the European Society for Paediatric Gastroenterolo-
gy, Hepatology and Nutrition (ESPGHAN), wanders away
from the old one, in which enteropathy (i.e. villous atrophy)
had the central role. Yet, intolerance to gluten remains the
cornerstone of the definition. Gluten is the collective name
for the alcohol-soluble protein fractionof wheat; it is a complex
and sticky (hence glue) conglomerate of mostly gliadins and
glutenins. Prolamins similar to gliadin are also present in other
grains, especially in rye (secalins), barley (hordeins), and oats
(avenins). In individuals carrying the DQ2 or DQ8 hetero-
dimer, the use of gluten-containing foods may lead to gluten-
specific hypersensitivity, resulting in an autoimmune process
which induces small-bowel mucosal damage. Complete elim-
ination of gluten from the diet alleviates the immune reaction
and provides clinical, serological and histological remission.
The diet should be followed for life. The first step in the
diagnosis is being acquainted with the disease and recognising
the symptoms.
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DOI 10.1007/s00431-012-1714-8Beyond CD Not all persons been found or claiming to expe-
rienceadversereactionwhileconsumingglutenorwheatprod-
ucts have CD. This may, however, be mainly applicable to
adults.In a very recentconsensus paper, aninternational group
of experts distinguished three main groups: autoimmune reac-
tions to gluten, wheat allergy and gluten sensitivity [71]. Au-
toimmune reactions, all with positive serology, included CD,
dermatitis herpetiformis and gluten ataxia. Wheat allergy was
primarily represented by bakers’ asthma and exercise-induced
wheat allergy, the latter being an IgE-mediated process result-
ing in acute reactions. Finally, in gluten sensitivity, symptoms
and reaction to a gluten-free diet might be indistinguishable
from those in CD—although especially neurological symp-
toms are reported as possible main presenting symptoms
[42]—butthecharacteristicIgAantibodiesaremissing,small-
bowel histology is normal and only about 50 % carry DQ2 or
DQ8 [90]. As gluten elimination is the only available method
to diagnose gluten sensitivity, much remains uncertain about
this condition [71, 90]. For instance, there is much debate
about a possible role for gluten sensitivity in children with
autism spectrum disorders [22].
Pathophysiology
Genetic background CD is strongly associated with certain
human leukocyte antigen class II haplotypes. HLA genes, the
human representation of the major histocompatibility complex,
are localised on the short arm of chromosome 6 [11]. These
genes are involved in the regulation of the immune response.
There are two types of HLA-DQ2 molecules, DQ2.5, encoded
by the DQ A1*0501/B1*02 allele, with a relative high risk of
CD and DQ2.2, encoded by DQ A1*0201/B1*02, with a
relatively low risk [84]. DQ2.5 is present in about 95 % of
C Dp a t i e n t s ,w i t hH L A - D Q 8a n dt oal e s s e re x t e n tD Q 2 . 2a n d
homozygosity for the HLA-DQ2 β-chain B1*02 accounting
f o rt h er e m a i n i n g5%[ 8, 75]. DQ2- and DQ8-positive gluten-
specific T lymphocytes recognise certain gluten peptides when
presented by antigen-presenting cells. The resulting inflamma-
tory response and tissue damage upregulate the activity of the
mucosal enzyme transglutaminase type 2 (TG2; formerly
called tissue transglutaminase). DQ2.5-positive antigen-
presenting cells cover a larger repertoire of gluten peptides to
T cells as compared to DQ2.2 (and DQ8) positive cells; in
addition, they bind more stably to gluten peptides [8, 84]. This
explains the strong correlation between DQ2.5 positivity and
CD.
Transglutaminase One of the typical properties of gluten
proteins is the excess presence of the amino acids proline
and glutamine. Proline is responsible for the compact tertiary
structure of gluten. Glutamine residues, carrying an extra
amino group, are deamidated by transglutaminase type 2,
which is activated as part of the first inflammatory response
[80]. DQ2 molecules bind stronger to the resulting glutamic
acid-enricheddeamidated peptidesthantothe native peptides,
resulting in increased stimulation of T cells; the ensuing
enhanced immune response results in an inflammatory reac-
tion in the small-bowel wall. The stages of this process have
been carefully established by Marsh [50].
Marsh classification The influx of T lymphocytes into the
epithelium (stage 1) is followed by the destruction of mu-
cosa cells, resulting in increased enterocyte turnover. At first,
increasedproductionensuesaswitnessedbycrypthyperplasia
(stage 2), but when the rate of cell destruction surpasses the
rate of cell renewal, also the villi become shorter leading to
increasing severity of villous atrophy (partial, stage 3a; sub-
total, stage 3b; total, stage 3c; Fig. 1)[ 50]. Malabsorption of
nutrients follows the loss of absorptive surface, which may
explain most of the symptoms of CD.
Other genetic and environmental factors Although the pres-
ence of DQ2 or DQ8, therefore, is more or less a conditio
sine qua non, these haplotypes are present in about 40 % of
the Western European population, while it is thought that 1 in
every 100–200 individuals has CD. So other factors, both
genetic and environmental, must be involved in the develop-
ment of CD. Obviously, a gluten-containing diet is one of
these. As far as genetics is concerned, it is estimated that the
associated HLA haplotypes represent 36–40 % of the genetic
risk of CD [66, 75, 81]. In addition, until now, some 40 genes
have been found to be associated with CD, increasing or
decreasing the risk of the disease [81, 82]. Interestingly, only
one third ofthe non-HLAgenes are exclusivelyrelated toCD,
two thirds being associated with a host of haematological,
metabolic, neurological, oncologic and especially immune-
related conditions [81]. Not surprisingly, the most extensive
associations were found with type 1 diabetes, rheumatoid
arthritis and Crohn’s disease.
It remains mostly unexplained, however, why the age at
which CD presents may vary so widely. Being considered
mainly a childhood disease until recently, presently the diag-
nosis is made more often in adults than in children [91].
Possibly the first immune response is elicited by non-specific
disturbance of the mucosal integrity, as may be caused by viral
gastroenteritis [41, 77].
Incidence
Increased awareness and improved diagnostic methods have
led to a greatly increased incidence of recognised CD. Where-
as in the Netherlands, for instance, only 25 years ago, CD was
considered a rare disease; the incidence of biopsy-proven CD
hasbeenrisenfrom0.1to0.2per1,000lifebirthsinthe1970s
1012 Eur J Pediatr (2012) 171:1011–1021and early 1980 to 0.54 in 1994 [28] and 1.1 in 2001 [76]. This
rise has continued up to the present day: while in the Nether-
lands in 1994, 105 children were diagnosed with CD; this has
risen to 301 in 2010 (resulting in an estimated incidencerate of
1.5 per 1,000) [73]. Yet, this still is the proverbial top of the
iceberg, as population-based studies in Western countries,
includingtheNetherlands,haveshownthatthetrueprevalence
of CD lies closer to 1 per100 than to 1 per 200[7,19,80]. This
implies that for every child diagnosed with CD, four others
have notbeen recognised. Althoughpartof these childrenmay
be symptom free, many will have unappreciated symptoms
compatible with CD. There are reasons to believe that the
increasing incidence of recognised CD is not merely a matter
of improved diagnostics, but also reflects a real increase in
disease prevalence [47, 70]. As in all autoimmune disorders,
girls outnumber boys in CD, with a ratio close of 2:1.
Effect of HLA type The relative risk of attracting CD as
determined by DQ2 and DQ8 is ‘dose dependent’.T h e
greatest relative risk (8.1) is encountered in individuals
homozygous for DQ2.5, the lowest (0.1) in individuals
heterozygous for DQ2.2 and DQ8, with a moderate tot
substantial (2.1–2.9) risk for DQ2.5 heterozygous individu-
als [87]. In general, therefore, DQ2 positivity refers to the
presence of DQ2.5, whereas DQ2.2-positive individuals are
rated ‘DQ2 negative’. Although the latter suggests an ex-
tremely low chance of developing CD, our own results
suggest that the risk of CD in DQ2.2-positive individuals
is comparable to that of individuals carrying DQ8 [57].
Relatives As a consequence of the genetic background of
CD, the condition is overrepresented in family members.
This is particularly true for monozygotic twins, with a
relative risk of 17 for the non-index twin to be concordant
[31]. About 10 % of CD patients have first-degree relatives
with CD. The odds for a family member of having CD, for
the greater part depend on the shared HLA haplotype, there-
fore ranging from <1 % for 40 % of the family members to
>20 % for 30 % [9]. In an extensive family study, Megnorni
et al. found that CD prevalence was 17.6 % in sisters of CD
patients, 10.8 % in brothers and 3.4 % in parents [48].
Siblings with DQ2 or DQ8 had a 20 % chance of having
CD (sisters, 29 %; brothers, 15 %), whereas for parents this
was 6 %.
Other groups with increased risk CD risk is increased in
children with certain syndromes, notably Down syndrome
[96], Williams syndrome and Turner syndrome [27], as well
as in children with autoimmune disorders, especially type 1
diabetes [89]—but also selective IgA deficiency [93], auto-
immune thyroid disease [53], autoimmune hepatitis [64] and
alopecia areata [60]. In children with type 1 autoimmune
hepatitis, the prevalence of CD is reported to average over
20 % [64].
Signs and symptoms
The clinical spectrum of CD is extremely heterogeneous. The
classical picture of a hypotonic, moody toddler with a flat
bottom, a huge belly and steatorrhoea may still be seen, but
most children present with subtler symptoms or are diagnosed
merely as a consequence of screening [67]. The age of diag-
nosis is extremely variable as well, from infancy, shortly after
the introduction of gluten into the diet, to old age. Although
symptomatic children generally present with gastrointestinal
and malnutrition-related symptoms, this is not always the case.
Not only the skin but also the liver, brain, lungs and other
Fig. 1 Marsh classification. From left to right: Marsh 00normal; 10increase of intraepithelial lymphocytes (IEL); 20increased IEL plus crypt
hyperplasia; 3a0partial villous atrophy, 3b0subtotal villous atrophy, 3c0total villous atrophy
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children may present with extraintestinal signs and symptoms
that could or could not be related to malabsorption, such as
growth failure, anaemia, decreased bone mass [83]a n dd e n t a l
enamel defects [94]. A systematic review found evidence for a
slightly increased risk in CD children of developing neurolog-
ical complications, such as headache, peripheral neuropathy
andwhite matter disease [45]. As a consequence, CD presently
is considered primarily a systemic disease [38].
Table 1 presents an overview of symptoms and signs
associated with CD. Not all of them justify in themselves
the inclusion of CD in the differential diagnosis; however,
abdominal pain, for instance, seldom, if ever, is the main
presenting symptom of CD [26, 29]. There seems to be no
correlation between symptomatology and HLA typing [87].
Silent, latent and potential coeliac disease Not all children
with CD are symptomatic, and not all children with positive
antibodies have CD. In the recently published ESPGHAN
guideline, the following definitions are proposed for chil-
dren not fulfilling all criteria for the diagnosis (Table 2)[ 38].
Children with antibodies, HLA typing and small-bowel
biopsy compatible with CD, but without symptoms that
would suggest the possibility of CD, are considered to have
silent CD. This would include relatives of CD patients
detected by screening. Children with compatible HLA typing
andwithoutactualenteropathy,withorwithoutsymptomsand
withorwithout antibodies, but withenteropathy atsomeother
time in their lives, are considered to have latent CD. Finally,
the presence of antibodies and HLA typing compatible with
CD, with or without symptoms, but without enteropathy, is
considered potential CD, which may or may not turn into
actual CD at a later stage [38].
Diagnosis
The huge variation in manifestations, many of them both non-
specific and potentially self-limiting, precludes the use of the
response to a gluten-free diet as a diagnostic tool. In young
children, for instance, functional diarrhoea, related to a sub-
optimal feeding pattern, will certainly improve with a bal-
anced diet, whether or not it contains gluten [43]. Moreover,
CD is a lifelong condition and therefore deserves a solid
diagnosis—which only can be established before treatment
is instituted. When, for some reason, a child is put on gluten-
free diet before the diagnosis is certain, the only way to prove
CD presently is by returning to a gluten-containing diet, thus
provoking the signs (and symptoms) of gluten toxicity.
Since the establishment of gluten as the main culprit [85]
and villous atrophy as the central abnormality [74], both
definition and diagnosis of CD have gone through a number
of changes. In 1969, a working group of ESPGAN devised
the ‘Interlaken criteria’, requiring three duodenal biopsies:
at diagnosis and before and after a period of gluten chal-
lenge [54]. These were revised in 1990, when the need of
gluten challenge was restricted mainly to children below
2 years of age at the time of diagnosis [92]. The availability
of increasingly reliable serologic tests, including transgluta-
minase type 2 antibodies [12], the notion that even in infants
a reliable diagnosis could be made without challenge [95]
and changing insight into the basic nature of CD [91] led to
Table 1 Symptoms and conditions associated with coeliac disease [38,
44, 59]
Classical presentation
Chronic diarrhoea with abdominal distension, growth retardation,
flat buttocks, anorexia and irritability
Atypical presentation
Persistent vomiting, nausea
Recurrent abdominal pain, abdominal distension
Chronic diarrhoea, persistent constipation
Involuntary weight loss
Growth retardation, pubertal delay
Chronic fatigue
Unexplained anaemia (iron, folic acid)
Dermatitis herpetiformis
Other associated symptoms and signs
Osteoporosis, unexplained fractures
Dental enamel hypoplasia
Aphthous stomatitis
Hypertransaminasemia
Polyneuropathy, epilepsy
White matter lesions
Cerebellar ataxia
Associated diseases and syndromes
Type 1 diabetes
Autoimmune thyroiditis
Autoimmune liver disease
Sjögren syndrome
Alopecia areata
IgA deficiency
Down syndrome
Turner syndrome
Williams syndrome
Table 2 Active, silent, latent and potential coeliac disease [38]
DQ2/8 Antibodies Histology Symptoms
Active CD + + + +
Silent CD + + + −
Latent CD + −/+ – (+ in the past) −/+
Potential CD + + −− /+
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certain strictly defined situations [38].
HLA typing As mentioned before, the great majority of CD
patients (95 %) carry the HLA DQ2 heterodimer in cis or trans,
DQ8 being present in most of the remaining patients [75]. In
Western populations, however, the prevalence of DQ2 and
DQ8 is high (up to 40 % of the general population carry either
DQ2 or DQ8, or both). As a result, the positive predictive value
ofthe presence of DQ2isverylowandthatofDQ8evenlower,
but the negative predictive value of the absence of both DQ2
and DQ8 is extremely high, to the point that it virtually
excludes CD. The value of HLA typing, therefore, is twofold:
on the one hand, it may serve to identify those children from
risk groups that might develop CD in the future; on the other
hand, it enables the exclusion of CD in part of the patients on
gluten-free diet without proper diagnosis. With the new
ESPGHAN guidelines, HLA typing has gained a third role,
i.e. as one of the criteria for CD in the diagnostic algorithm.
Serology Serologic testing is the first step in the diagnosis
of CD in symptomatic patients. Up to well into the 1990s,
one had to rely on antibodies against gliadin (IgA-AGA,
IgG-AGA) and reticulin (IgA-ARA) [5]. These were, how-
ever, neither specific nor sensitive enough to be useful in the
diagnostic work-up of suspected CD patients. In recent
years they have been replaced by tests for antiendomysium
(EmA) and anti-TG2 (TG2A). The latter two are extremely
specific and sensitive and therefore have positive and neg-
ative predictive values that come close to 100 % [72]. The
difference between these two antibodies is a relative one,
mainly based on different assessment techniques. In fact,
transglutaminase type 2 has been identified as the endomy-
sial autoantigen in CD [23]. Interestingly, other transgluta-
minases may play a role in extraintestinal CD: TG3,
expressed in skin cells and found in relation with dermatitis
herpetiformis, and TG6, expressed by central nervous system
neurons and probably related to gluten ataxia, epilepsy and
intracerebral calcifications [9, 42].
Although the level of antibodies isrelated tothe severity of
the mucosal lesions, in active CD, as a rule, high titres of IgA-
EmA and IgA-TG2A are present. In the new ESPGHAN
guidelines, TG2A levels exceeding 10 times the cut-off and
confirmedinanindependentbloodsamplebyEmAtestingare
the first requirement for a CD diagnosis without duodenal
biopsy in symptomatic children. In IgA-deficient patients,
IgG-EmA and IgG-TG2A determination can be used instead,
as well as the assessment of IgG antibodies against deami-
dated gliadin peptides (DGPA). After the institution of a
gluten-free diet, all serological markers will disappear, al-
though especially for EmA it may take several years before
they disappear completely [36]. In children under 2 years of
age, although antigliadin antibodies seem to perform slightly
better than EmA and TG2A [49], the new ESPGHAN guide-
lines discourage the use of these tests and recommend the use
of IgG-DGPA instead [38]. The sensitivity of DGPA in this age
group seems to be comparable to that of TG2A and EmA [68].
Small-bowel biopsy The central role of histological exami-
nation in CD has been stressed over and over in the past [25,
35, 54, 62, 69, 92]. The diagnosis of CD was based on the
presence of villous atrophy in combination with crypt hy-
perplasia [54, 92]. A great step forward was made by the
introduction of the Marsh criteria [50, 51], which in slightly
revised form remain the base of histological interpretation of
inflammatory small-bowel lesions (Fig. 1)[ 52, 62]. The
interpretation of small-bowel histology remains to be a
challenge, however, and should be performed in an experi-
enced laboratory [4]. Moreover, the diagnosis of CD should
never be based on histology alone; the clinical picture, the
serology and the effects on both of gluten-free diet should be
taken into account as well [17].
The first guidelines required gluten challenge some years
after the introduction of gluten-free diet in order to prove the
persistence ofsmall-bowelglutensensitivity [54]. Afterit was
shown that (temporary) villous atrophy due to other causes
was found only in infants [32], in the next guideline, the
demandforglutenchallengewasconfinedtochildrenyounger
than 2 years at the age of diagnosis [92]. The subsequent
advances in serologic testing as well as more recent data
[95], however, prompted most researchers to drop the require-
ment for gluten challenge in younger children as well.
The next step was challenging the need for small-bowel
biopsy. It was shown in several studies that high (>10 times
the upper limit of normal) TG2A levels had high positive
predictive values for the presence of villous atrophy in
children with symptoms suggestive of CD [20, 34, 88].
Similar results were reported in adults [88, 97]. This had
led the ESPGHAN working group to develop new algo-
rithms for the diagnosis of CD [38]. It is estimated that
these new guidelines lead to the reduction of the need for
intestinal biopsies by 20–30 % [38, 97].
In the past it was considered necessary to obtain jejunal
biopsies, which required the use of suction capsules [63].
Although already in the 1980s, reports were published con-
firming the usefulness of duodenal suction biopsies obtained
during endoscopy [10], it was only at the end of the last
century that forceps biopsies were generally considered
adequate [79]. Presently, duodenal biopsies mostly are
obtained during endoscopy under general anaesthesia,
which is a quick and safe procedure.
Selection of individuals fordiagnostic testing Thesymptom-
atology ofCDinchildrenisextremely variableand apartfrom
the now rare ‘classic’ complex of flat-buttocked, large-bellied
growth-retarded infants with diarrhoea and bad temper, there
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CD. Weight loss, abdominal pain and lassitude have become
more prevalent [76], whereas many children express only a
single symptom, such as growth retardation and therapy-
resistant anaemia (Table 1). In view of the high prevalence
of CD, therefore, it is wise to keep a low threshold for
serologic testing in children presenting with as yet unex-
plained symptoms. On the other hand, this will result in a
certain percentage of chance findings: children who are prov-
en to have CD but with unrelated presenting symptoms that
therefore risk to persist despite the institution of a gluten-free
diet. A second group of children to be tested are those with
enhanced risk of CD: children with first-degree relatives with
CD and children with associated syndromes or other autoim-
mune disorders, especially diabetes mellitus type 1 (Table 1).
Algorithms Based on current insights into pathophysiology
and diagnostic performance, the ESPGHAN working group
has developed two algorithms for the diagnostic work-up of
CD in symptomatic children and children with increased
risk of CD (Figs. 2 and 3)[ 38]. Important points are the
crucial role for HLA typing and the importance of high
TG2A levels in combination with positive EmA as a means
of eliminating the need of biopsy in a subset of children.
Different from the new ESPGHAN guidelines, however, we
prefer to take all the necessary blood samples during the first
visit, which is more acceptable to the child and the parents.
Depending on the results of TG2A testing, we proceed with
other tests following the algorithm. It should be noted that in
children with increased risk but without typical symptoms,
duodenal biopsies are always necessary (Fig. 2).
Gluten challenge With the new insights into CD, there is no
need to perform gluten challenge unless there is serious
doubt about the diagnosis of CD. Gluten challenge still
should be performed in children with villous atrophy con-
sistent with CD, but without positive serology, as there are
other conditions leading to villous atrophy [38]. Gluten
challenge is also inevitable in children who are placed on
a gluten-free diet without proper diagnostic work-up. A
third group soliciting for gluten challenge are the (older)
children who deny the diagnosis because they experience no
adverse effects when consuming gluten-containing snacks.
With proper understanding, they may accept their diet when
they are confronted with the detrimental results of gluten
consumption. Challenge should not be performed before the
age of 5 years and during puberty [38].
Treatment
At present, a strictly gluten-free diet is the only available
effective treatment for CD. It is, however, virtually impos-
sible to maintain a diet that is completely devoid of gluten,
Fig. 2 Algorithm for the
diagnosis of coeliac disease in
symptomatic children. TG2A
transglutaminase type 2
antibodies, EmA endomysium
antibodies, DGPA deamidated
gliadin peptide antibodies,
HLA human leukocyte antigen,
N upper limit of normal,
+ present, − absent, Marsh
Marsh classification
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commercially available products, ranging from sauces and
sausages to soups and chips, gluten is used as a protein filler.
In addition, the omnipresence of wheat and wheat starch in
production lines may lead to cross-contamination of cereals
and other originally gluten-free products [13]. It is, therefore,
extremely difficult to achieve a diet completely devoid of
gluten. From a practical point of view, products may be called
glutenfreewhentheyaretoleratedbythegreatmajorityofCD
patients—tolerated not only in terms of symptoms but also of
small-bowel histology and quality of life. Unfortunately, there
seems to be a grey zone of gluten tolerance between CD
patients.Whilesomepatientsmaytolerateabout35mggluten
per day [16], others seem to be intolerant to smaller amounts
[1]. For practical reasons, these daily amounts have to be
translated into food product concentrations.
Definition of ‘gluten free’ With increasing sensitivity of de-
termination techniques for traces of gluten in foods, the
t h r e s h o l df o rw h a ti sa l l o w e dt ob ec a l l e dg l u t e nf r e ei s
changing. The Codex Alimentarius standard on gluten-free
products has been revised in 2008, allowing gluten concen-
trationsinconsumerfoods labelledglutenfree upto20 mg/kg
(20 ppm), analogous to 10 mg prolamin per kg—ar e d u c t i o n
to 10 % of the formerly accepted level [15]. ‘Gluten-free’
wheat starch has been shown safe for use to the majority of
CDpatients[65].Withthisthreshold,complete adherencetoa
gluten-free diet will result in gluten intakes amply below
10 mg per day. A second limit—100 ppm—is used to desig-
nate foods with very low gluten content. These should, how-
ever, not appear on the menu of CD patients.
Oats Traditionally, wheat, rye, barley and oats are considered
the grains that should be avoided by CD patients. Probably,
however, oats used in early studies was heavily contaminated
with other grains [24]. Recently, oats has been at least partially
acquittedfrombeingharmfultoCDpatients[3].Invivostudies
confirm that contamination-free oats is not harmful to at least
the majority of CD patients [33, 37]. Specially grown and
processed oats could, therefore, be included in the gluten-free
dietofCDpatients,providedthattheybefollowedclosely[24].
Future therapeutic options Although gluten avoidance pres-
ently is the only viable option for the treatment of CD, the
increasing knowledge of the pathophysiology of CD has
created the perspective of different therapeutic approaches,
including decreasing gluten exposure, diminishing intestinal
permeability and modulation of the immune response [44].
Especially the use of AN-PEP, a prolyl endoprotease derived
from the fungus Aspergillus niger, which is capable of
instantaneous degradation of gluten within the acid environ-
ment of the stomach, seems promising [55]. None of these
novel strategies, however, is supposed to completely abro-
gate the need of following a gluten-free diet [18].
Fig. 3 Algorithm for the
diagnosis of coeliac disease in
children with increased genetic
risk and with associated
immune disorders. TG2A
transglutaminase type 2
antibodies, EmA endomysium
antibodies, HLA human
leukocyte antigen, N upper limit
of normal, Marsh Marsh
classification
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There is general consensus that children following a gluten-
free diet should be followed up on a regular basis. Both the
paediatrician and the dietician should be involved. The
dietician is familiar with all practical aspects of the diet,
including facets as how to read labels of food items, how to
keep a corner of the kitchen gluten free and how to prevent
contamination when cooking for the whole family. The
paediatrician follows growth and well-being of the child,
identifies secondary problems and performs blood tests,
including follow-up on serology and thyroid function tests
when indicated (Fig. 4). The gluten-free diet is relatively
low in fibre, and many children experience some defecation
problems with constipation or abdominal pain in the first
months after starting the diet. Usually this is easily con-
trolled by prescribing macrogol for a few months.
One critical point that should be addressed regularly,
especially during puberty and when children exchange pri-
mary school for high school, is adherence to the diet. The
more the parents are confident that the gluten-free diet is
essential for their child’s well-being, the better the diet is
accepted by the child. But during puberty many children
may start to experiment with gluten-containing snacks, in an
attempt not to draw attention to their peculiar diet. Although
this may be inevitable, it may help to openly discuss the
challenges the child has to cope with. This may also be a
reason to propose a formal gluten challenge, in order to
convince the patient of the necessity of the diet.
Prognosis
In children, an adequate diet will invariably result in com-
plete disappearance of symptoms, including full recovery of
predicted height growth [21], and serological and histological
normalisation. While clinical symptoms usually dissolve
within a few weeks (although catch-up growth may only be
completed after several years), it may take some years for
histology and especially serology to return to normal. Refrac-
tory CD, with persistence of villous atrophy, which is seen in
2–5 % of CD patients diagnosed in adulthood [78], is ex-
tremely rare in children [56]. Type II refractory CD presents
with aberrant intraepithelial lymphocytes and is associated
with enteropathy-associated T-cell lymphoma [78]. Several
reports mention increased mortality in CD patients; it is
thought that the risk of mortality decreases over time with
strict adherence to a gluten-free diet [6, 30].
Prevention
The earliest suggestion that infant feeding practices might
have a role in the epidemiology of CD is to be found in
letters to the Lancet in 1980 [46]. The authors reported a
decline in (classical) CD cases after the recommendation of
later cereal introduction and the encouragement of breast
feeding. Although subsequently it was suggested to be mere
postponement of symptoms, the analysis of an epidemic of
CD in children under 2 years of age in the Swedish birth
Fig. 4 Follow-up of
coeliac disease
1018 Eur J Pediatr (2012) 171:1011–1021cohorts of 1984–1996 confirmed the impact of infant feeding
practices on CD incidence [39, 40]. In the 1993 Swedish birth
cohort, investigated at the age of 12 years, a total incidence of
CD was found of 3 %, three times higher than expected,
confirming the epidemic nature of the rise in incidence [58].
Ameta-analysis oftheseand other studies confirmedthatboth
length of breastfeeding and breastfeeding at the time of intro-
duction of gluten offer protection against CD [2]. In addition,
the timing of gluten introduction seems to play a role as well,
with the smallest risk of CD development obtained with the
gradual introduction of gluten between 4 and 6 months of age
[61]. These results could be explained by the presence of non-
degradedgliadinaswellasgliadin–antigliadinIgAcomplexes
in breastmilk [14], which could help infants at risk to develop
tolerance to gluten [86].
Conclusion
Better insight into the pathophysiology and better diagnostic
toolshaveledtochangesinthediagnosticwork-upofchildren
suspected of CD. In around one quarter of symptomatic chil-
dren, under strictly defined conditions, small-bowel biopsy
may be omitted. Given the persistence of gluten sensitivity
throughout life and the burden of (unnecessary) dietary treat-
ment, however, utmost care should be exerted when diagnos-
ing this condition and proper follow-up is essential.
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